NVO - Novo Nordisk A/S

NYSE - NYSE Delayed Price. Currency in USD
48.69
-0.03 (-0.06%)
At close: 4:02PM EDT

48.47 -0.23 (-0.47%)
Pre-Market: 8:30AM EDT

Stock chart is not supported by your current browser
Previous Close48.72
Open49.00
Bid48.41 x 900
Ask48.47 x 800
Day's Range48.67 - 49.04
52 Week Range41.03 - 58.37
Volume632,020
Avg. Volume1,421,308
Market Cap117.32B
Beta0.82
PE Ratio (TTM)19.18
EPS (TTM)2.54
Earnings DateN/A
Forward Dividend & Yield1.28 (2.61%)
Ex-Dividend Date2018-03-23
1y Target Est60.40
Trade prices are not sourced from all markets
  • We have a policy of not taking list price increases of ab...
    CNBC Videos20 days ago

    We have a policy of not taking list price increases of ab...

    Lars Fruergaard speaks about earnings and his company's U.S. business amid changing regulation.

  • GlobeNewswire39 minutes ago

    Report: Developing Opportunities within El Pollo Loco, Chemed, Novo Nordisk A/S, FactSet Research, Fair Isaac, and HCP — Future Expectations, Projections Moving into 2018

    NEW YORK, May 22, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of El ...

  • Top Research Reports for Walmart, AT&T & Novo Nordisk
    Zacks4 days ago

    Top Research Reports for Walmart, AT&T & Novo Nordisk

    Top Research Reports for Walmart, AT&T & Novo Nordisk

  • AstraZeneca’s 1Q18 Earnings: Analysts’ Estimates
    Market Realist7 days ago

    AstraZeneca’s 1Q18 Earnings: Analysts’ Estimates

    AstraZeneca (AZN) is one of the leading pharmaceutical companies that deals with primary care and specialty care products. Though it’s headquartered in London, England, the company reports its revenue in US dollars. The company is set to release its 1Q18 earnings on May 18.

  • Novo Nordisk Fights Payer Pressure With New Meds
    Motley Fool15 days ago

    Novo Nordisk Fights Payer Pressure With New Meds

    Sales of older medications are on the decline, but newer medications helped the revenue line grow at constant exchange rates.

  • Is Novo Nordisk A/S (NYSE:NVO) A Buy At Its Current PE Ratio?
    Simply Wall St.15 days ago

    Is Novo Nordisk A/S (NYSE:NVO) A Buy At Its Current PE Ratio?

    Novo Nordisk A/S (NYSE:NVO) trades with a trailing P/E of 18.9x, which is lower than the industry average of 23.5x. While NVO might seem like an attractive stock to buy,Read More...

  • Novo Nordisk (NVO) Q1 2018 Earnings Conference Call Transcript
    Motley Fool19 days ago

    Novo Nordisk (NVO) Q1 2018 Earnings Conference Call Transcript

    NVO earnings call for the period ending March 31, 2018.

  • NVS and NVO: Which Has Higher Upside Potential?
    Market Realist20 days ago

    NVS and NVO: Which Has Higher Upside Potential?

    Novartis’s (NVS) EV (enterprise value) is $206.9 billion and its EV-to-revenue ratio is 4.1. The stock is trading at a forward PE (price-to-earnings) ratio of 13.3, and its PEG (price-to-earnings-to-growth) ratio is 2.2. At present, Novartis’ price-to-sales ratio is 3.6, and its price-to-book ratio is 2.4.

  • These Pharma Stocks Offer the Most Upside Potential
    Market Realist20 days ago

    These Pharma Stocks Offer the Most Upside Potential

    In 2018, stock markets, especially in the pharmaceutical sector, have seen heightened volatility. While the S&P 500 has recovered a bit from its fluctuation this year and has fallen only 0.12% year-to-date, the iShares US Pharmaceuticals ETF (IHE), SPDR S&P Pharmaceuticals ETF (XPH), VanEck Vectors Pharmaceutical ETF (PPH), and First Trust NASDAQ Pharmaceuticals ETF (FTXH) have fallen 4.4%, 5.9%, 3.5%, and 2.5%, respectively, indicating that pharma stocks are underperforming the overall market.

  • Novo Nordisk (NVO) Beats Q1 Earnings Estimates, Sales Miss
    Zacks20 days ago

    Novo Nordisk (NVO) Beats Q1 Earnings Estimates, Sales Miss

    Novo Nordisk's (NVO) first-quarter 2018 results beat earnings, but missed on revenue estimates.

  • Reuters20 days ago

    Drugmaker Novo Nordisk beats first quarter profit expectations, nudges up 2018 outlook

    Denmark's Novo Nordisk (NOVOb.CO), the world's biggest maker of diabetes drugs, reported first-quarter operating profit above expectations on Wednesday and raised the lower end of its 2018 sales and profit forecast. Operating profit fell 8 percent to 12.4 billion Danish crowns (1.5 billion pounds) in the January to March quarter compared with a year ago, hit by the depreciation of the U.S. dollar, but beat an average 11.8 billion crown forecast in a Reuters poll of analysts. With its traditional insulin treatments in the firing line due to U.S. price pressure, Novo Nordisk is pinning hopes for growth on new obesity drugs and a once-weekly injection and tablet version of its semaglutide drug.

  • GlaxoSmithKline’s 1Q18 Earnings: Consumer Healthcare Business
    Market Realist22 days ago

    GlaxoSmithKline’s 1Q18 Earnings: Consumer Healthcare Business

    GlaxoSmithKline’s (GSK) Consumer Healthcare business includes various products for oral health, wellness, nutrition, and skin health. The consumer healthcare business reported revenues of ~2.0 billion pounds in 1Q18, a ~3% decrease compared to 1Q17.

  • GlaxoSmithKline’s Pharmaceutical Business in 1Q18
    Market Realist22 days ago

    GlaxoSmithKline’s Pharmaceutical Business in 1Q18

    GlaxoSmithKline’s (GSK) Pharmaceuticals business includes various Immuno-inflammation products, HIV products, Respiratory products, and Established products. The Pharmaceuticals business segment reported revenues of ~4.0 billion pounds in 1Q18.

  • Grifols, Novo expansions prompt $1.3M renovation of JoCo training center
    American City Business Journals25 days ago

    Grifols, Novo expansions prompt $1.3M renovation of JoCo training center

    Grifols and Novo Nordisk are expanding in the Triangle, and so is the training center that produces talent for the biomanufacturing giants.

  • Analyst Recommendations for Novo Nordisk in April
    Market Realist25 days ago

    Analyst Recommendations for Novo Nordisk in April

    In March, Novo Nordisk (NVO) received an exclusive worldwide license for EpiDestiny’s sickle cell disease program, EPI01. Novo Nordisk will pay more than $400 million as an upfront payment to EpiDestiny for the license. EpiDestiny will also receive development and sales milestone payments from Novo Nordisk along with royalties on net sales of the product.

  • How Is Novo Nordisk Positioned before 1Q18?
    Market Realist25 days ago

    How Is Novo Nordisk Positioned before 1Q18?

    In 4Q17, Novo Nordisk (NVO) generated revenues of 28 billion Danish kroner, which is a ~2% decline on a YoY (year-over-year) basis.

  • Novo Nordisk’s Saxendra Could Witness Solid Growth in 2018
    Market Realist26 days ago

    Novo Nordisk’s Saxendra Could Witness Solid Growth in 2018

    In 4Q17, Novo Nordisk’s (NVO) Saxendra generated revenues of 697 million Danish kroner, which reflected a ~38% YoY (year-over-year) growth in local currency.

  • Novo Nordisk’s Hemophilia Segment Could See Steady 2018 Growth
    Market Realist26 days ago

    Novo Nordisk’s Hemophilia Segment Could See Steady 2018 Growth

    In 4Q17, Novo Nordisk’s (NVO) hemophilia drugs NovoSeven and NovoEight generated revenues of 2.4 billion Danish kroner and 274 billion Danish kroner, respectively. That’s a ~3% and 1% YoY (year-over-year) growth in local currency.

  • GlobeNewswire26 days ago

    Emisphere Amends License Agreement with Novo Nordisk

    ROSELAND, N.J., April 26, 2018-- Emisphere Technologies, Inc. today announced that it has amended its existing 2015 Development and License Agreement with Novo Nordisk A/S for the development and commercialization ...

  • Novo Nordisk’s Victoza Could See High Growth in 2018
    Market Realist26 days ago

    Novo Nordisk’s Victoza Could See High Growth in 2018

    In 4Q17, Novo Nordisk’s (NVO) Victoza generated revenues of 6.3 billion Danish kroner, which reflected a ~25% YoY (year-over-year) growth in local currency.

  • Analysts’ Views on Sanofi, Pre-1Q18 Earnings Release
    Market Realist27 days ago

    Analysts’ Views on Sanofi, Pre-1Q18 Earnings Release

    In 1Q18, analysts expect Sanofi’s (SNY) revenue to fall ~6.6% YoY (year-over-year) to 8.1 billion euros from 8.7 billion euros, and its earnings per share to fall to 1.13 euros from 1.42 euros. Sanofi’s stock price has fallen ~9.4% over the last 12 months and ~7.1% year-to-date. Analysts’ price target of $47.67 suggests the stock could return ~19.2% over the next 12 months based on its price of $39.95 on April 23.

  • A Review of Novo Nordisk’s Modern Insulin
    Market Realist27 days ago

    A Review of Novo Nordisk’s Modern Insulin

    Novo Nordisk’s (NVO) modern insulins include NovoRapid, Levemir, and NovoMix. In 4Q17, its modern insulins generated revenues of 10.4 billion Danish kroner, which is a ~9% YoY (year-over-year) decline in local currency.

  • Novo Nordisk’s New-Generation Insulins: Growth Driver for 2018?
    Market Realist27 days ago

    Novo Nordisk’s New-Generation Insulins: Growth Driver for 2018?

    Novo Nordisk’s (NVO) new-generation insulin portfolio consists of Tresiba, Xultophy, Ryzodeg, and Fiasp.

  • Tresiba Could Significantly Drive Novo Nordisk’s Revenue in 2018
    Market Realist28 days ago

    Tresiba Could Significantly Drive Novo Nordisk’s Revenue in 2018

    In 4Q17, Novo Nordisk’s (NVO) Tresiba generated revenues of 1.9 billion Danish kroner, which is a ~48% YoY (year-over-year) growth in local currency.